Last reviewed · How we verify

NCT00088738

Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ

Completed Phase 1 Last updated 2 July 2017
What this trial tests

Phase 1 trial testing [18F] SPA-RQ in Panic Disorder in 84 participants. Completed in 10 September 2008.

Timeline
27 July 2004
10 September 2008

Quick facts

Lead sponsorNational Institute of Mental Health (NIMH)
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Primary purposetreatment
Enrollment84
Start date27 July 2004
Estimated completion10 September 2008
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

National Institute of Mental Health (NIMH)

Who can join

Adults 18 to 65, any sex, with Panic Disorder or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to observe the effects of a panic attack in patients with panic disorders and to demonstrate the involvement of Substance P in panic disorder, and thereby, further our understanding of its role in this illness. We will measure levels of Substance P in the brain by obtaining pictures of the brain using PET and MRI....

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Panic Disorder

Currently open trials in the same condition.

Other National Institute of Mental Health (NIMH) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00088738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing